てんかん治療薬の市場規模、シェア、動向分析レポート:製品別(第一世代抗てんかん薬、第二世代抗てんかん薬、第三世代抗てんかん薬)、地域別、セグメント別予測、2023年~2030年Epilepsy Drugs Market Size, Share & Trends Analysis Report By Product (First Generation Anti-epileptics, Second Generation Anti-epileptics, Third Generation Anti-epileptics), By Region, And Segment Forecasts, 2023 - 2030 てんかん治療薬市場の成長と動向 Grand View Research, Inc.の最新レポートによると、てんかん治療薬の世界市場規模は、2023年から2030年にかけて年平均成長率5.1%を記録し、2030年には153.5億米ドルに達する... もっと見る
1~3営業日
サマリーてんかん治療薬市場の成長と動向Grand View Research, Inc.の最新レポートによると、てんかん治療薬の世界市場規模は、2023年から2030年にかけて年平均成長率5.1%を記録し、2030年には153.5億米ドルに達すると予測されています。てんかん発作の治療に有効な新薬の開発に対する政府資金の増加は、てんかん治療薬市場の成長にとってインパクトの大きいレンダリングドライバーである。米国てんかん協会(AES)は、米国神経学会、てんかん財団、グラス財団などの他の組織と連携して、研究開発活動に資金を提供し、さまざまなプログラムを通じて医師に治療ラインの認識トレーニングを提供しています。 さらに、Epilepsy Foundation、American Epilepsy Society、Epilepsy Association of Central Florida、CURE Epilepsy、Anita Kaufmann Foundationなどの団体が実施する様々な啓発プログラムは、診断率と治療率をさらに加速させています。このことは、予測期間中の市場成長を促進すると予想される。 てんかん治療薬市場レポートハイライト - 第二世代の抗てんかん薬は、第二の急成長セグメントとなる見込み。このセグメントには、Lamotrigine(Lamictal)、Levetiracetam(Keppra)、Brivaracetam(Briviact)、Perampanel(Fycompa)などが含まれる。 - 第3世代の抗てんかん薬セグメントは、2022年に約39.3%という最大の売上シェアを占めた。同分野の成長の主な要因としては、作用機序が改善され副作用の少ない有効性の高い薬剤の上市や、新たなパイプライン薬剤の上市待ちなどが挙げられる。 - 2022年の売上高シェアは、北米が約45%と最も高く、市場を支配している。同地域ではてんかんの有病率が高く、罹患者数が多いことが、てんかん治療薬市場の主な牽引要因となっている。 - アジア太平洋地域は、予測期間においてCAGR 6.3%と最も高い成長率で拡大すると推定される。てんかんに関するセクター間世界行動計画、てんかんに対する世界キャンペーンなどの政府主導の取り組みや、新世代の抗てんかん薬の発売が、同地域における同市場の成長を促進する原動力となっています。 目次Table of ContentsChapter 1. Methodology and Scope 1.1. Market Segmentation & Scope 1.1.1. Product 1.1.2. Regional scope 1.1.3. Estimates and forecast timeline 1.2. Research Methodology 1.3. Information Procurement 1.3.1. Purchased database 1.3.2. GVR’s internal database 1.3.3. Secondary sources 1.3.4. Primary research 1.3.5. Details of primary research 1.4. Information or Data Analysis 1.4.1. Data analysis models 1.5. Market Formulation & Validation 1.6. Model Details 1.7. List of Secondary Sources 1.8. List of Primary Sources 1.9. Objectives 1.9.1. Objective 1 1.9.2. Objective 2 Chapter 2. Executive Summary 2.1. Market Outlook 2.2. Segment Outlook 2.2.1. Product outlook 2.2.2. Regional outlook 2.3. Competitive Insights Chapter 3. Market Variables, Trends & Scope 3.1. Market Lineage Outlook 3.1.1. Parent market outlook 3.1.2. Related/ancillary market outlook 3.2. Penetration & Growth Prospect Mapping 3.3. Market Dynamics 3.3.1. Market driver analysis 3.3.2. Market restraint analysis 3.4. Penetration & Growth Prospect Mapping 3.5. Global Epilepsy Drug Market Analysis Tools 3.5.1. Industry Analysis - Porter’s Five Forces 3.5.1.1. Supplier power 3.5.1.2. Buyer power 3.5.1.3. Substitution threat 3.5.1.4. Threat of new entrant 3.5.1.5. Competitive rivalry 3.5.2. PESTEL Analysis 3.5.2.1. Political landscape 3.5.2.2. Technological landscape 3.5.2.3. Economic landscape Chapter 4. Epilepsy Drugs Market: Product Estimates & Trend Analysis 4.1. Epilepsy Drug Market: Key Takeaways 4.2. Epilepsy Drug Market: Product Movement & Market Share Analysis, 2022 & 2030 4.3. First Generation Anti-epileptics 4.3.1. First generation anti-epileptics market estimates and forecasts, 2018 to 2030 (USD Million) 4.4. Second Generation Anti-epileptics 4.4.1. Second generation anti-epileptics market estimates and forecasts, 2018 to 2030 (USD Million) 4.5. Third Generation Anti-epileptics 4.5.1. Third generation anti-epileptics market estimates and forecasts, 2018 to 2030 (USD Million) Chapter 5. Epilepsy Drugs Market: Regional Estimates & Trend Analysis, by Drug 5.1. Regional Outlook 5.2. Epilepsy Drug Market by Region: Key Marketplace Takeaways 5.3. North America 5.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million) 5.3.2. U.S. 5.3.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million) 5.3.3. Canada 5.3.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million) 5.4. Europe 5.4.1. UK 5.4.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million) 5.4.2. Germany 5.4.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million) 5.4.3. France 5.4.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million) 5.4.4. Italy 5.4.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million) 5.4.5. Spain 5.4.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million) 5.4.6. Sweden 5.4.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million) 5.4.7. Norway 5.4.7.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million) 5.4.8. Denmark 5.4.8.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million) 5.5. Asia Pacific 5.5.1. Japan 5.5.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million) 5.5.2. China 5.5.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million) 5.5.3. India 5.5.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million) 5.5.4. Australia 5.5.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million) 5.5.5. Thailand 5.5.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million) 5.5.6. South Korea 5.5.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million) 5.6. Latin America 5.6.1. Brazil 5.6.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million) 5.6.2. Mexico 5.6.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million) 5.6.3. Argentina 5.6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million) 5.7. MEA 5.7.1. Saudi Arabia 5.7.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million) 5.7.2. South Africa 5.7.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million) 5.7.3. UAE 5.7.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million) 5.7.4. Kuwait 5.7.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million) Chapter 6. Competitive Landscape 6.1. Recent Developments & Impact Analysis, By Key Market Participants 6.2. Market Participant Categorization 6.2.1. UCB S.A., Belgium 6.2.1.1. Company Overview 6.2.1.2. Financial Performance 6.2.1.3. Product Benchmarking 6.2.1.4. Strategic Initiatives 6.2.2. Sanofi 6.2.2.1. Company Overview 6.2.2.2. Financial Performance 6.2.2.3. Product Benchmarking 6.2.2.4. Strategic Initiatives 6.2.3. Pfizer, Inc. 6.2.3.1. Company Overview 6.2.3.2. Financial Performance 6.2.3.3. Product Benchmarking 6.2.3.4. Strategic Initiatives 6.2.4. Otsuka America Pharmaceutical, Inc. 6.2.4.1. Company Overview 6.2.4.2. Financial Performance 6.2.4.3. Product Benchmarking 6.2.4.4. Strategic Initiatives 6.2.5. Eisai Co., Ltd. 6.2.5.1. Company Overview 6.2.5.2. Financial Performance 6.2.5.3. Product Benchmarking 6.2.5.4. Strategic Initiatives 6.2.6. Novartis AG 6.2.6.1. Company Overview 6.2.6.2. Financial Performance 6.2.6.3. Product Benchmarking 6.2.6.4. Strategic Initiatives 6.2.7. Abbott Laboratories, Inc. 6.2.7.1. Company Overview 6.2.7.2. Financial Performance 6.2.7.3. Product Benchmarking 6.2.7.4. Strategic Initiatives 6.2.8. Sanofi Aventis S.A. 6.2.8.1. Company Overview 6.2.8.2. Financial Performance 6.2.8.3. Product Benchmarking 6.2.8.4. Strategic Initiatives 6.2.9. GlaxoSmithKline plc 6.2.9.1. Company Overview 6.2.9.2. Financial Performance 6.2.9.3. Product Benchmarking 6.2.9.4. Strategic Initiatives 6.2.10. Sunovion Pharmaceuticals, Inc. 6.2.10.1. Company Overview 6.2.10.2. Financial Performance 6.2.10.3. Product Benchmarking 6.2.10.4. Strategic Initiatives 6.2.11. Jazz Pharmaceuticals plc 6.2.11.1. Company Overview 6.2.11.2. Financial Performance 6.2.11.3. Product Benchmarking 6.2.11.4. Strategic Initiatives 6.2.12. Neurelis, Inc. 6.2.12.1. Company Overview 6.2.12.2. Financial Performance 6.2.12.3. Product Benchmarking 6.2.12.4. Strategic Initiatives
SummaryEpilepsy Drugs Market Growth & Trends Table of ContentsTable of ContentsChapter 1. Methodology and Scope 1.1. Market Segmentation & Scope 1.1.1. Product 1.1.2. Regional scope 1.1.3. Estimates and forecast timeline 1.2. Research Methodology 1.3. Information Procurement 1.3.1. Purchased database 1.3.2. GVR’s internal database 1.3.3. Secondary sources 1.3.4. Primary research 1.3.5. Details of primary research 1.4. Information or Data Analysis 1.4.1. Data analysis models 1.5. Market Formulation & Validation 1.6. Model Details 1.7. List of Secondary Sources 1.8. List of Primary Sources 1.9. Objectives 1.9.1. Objective 1 1.9.2. Objective 2 Chapter 2. Executive Summary 2.1. Market Outlook 2.2. Segment Outlook 2.2.1. Product outlook 2.2.2. Regional outlook 2.3. Competitive Insights Chapter 3. Market Variables, Trends & Scope 3.1. Market Lineage Outlook 3.1.1. Parent market outlook 3.1.2. Related/ancillary market outlook 3.2. Penetration & Growth Prospect Mapping 3.3. Market Dynamics 3.3.1. Market driver analysis 3.3.2. Market restraint analysis 3.4. Penetration & Growth Prospect Mapping 3.5. Global Epilepsy Drug Market Analysis Tools 3.5.1. Industry Analysis - Porter’s Five Forces 3.5.1.1. Supplier power 3.5.1.2. Buyer power 3.5.1.3. Substitution threat 3.5.1.4. Threat of new entrant 3.5.1.5. Competitive rivalry 3.5.2. PESTEL Analysis 3.5.2.1. Political landscape 3.5.2.2. Technological landscape 3.5.2.3. Economic landscape Chapter 4. Epilepsy Drugs Market: Product Estimates & Trend Analysis 4.1. Epilepsy Drug Market: Key Takeaways 4.2. Epilepsy Drug Market: Product Movement & Market Share Analysis, 2022 & 2030 4.3. First Generation Anti-epileptics 4.3.1. First generation anti-epileptics market estimates and forecasts, 2018 to 2030 (USD Million) 4.4. Second Generation Anti-epileptics 4.4.1. Second generation anti-epileptics market estimates and forecasts, 2018 to 2030 (USD Million) 4.5. Third Generation Anti-epileptics 4.5.1. Third generation anti-epileptics market estimates and forecasts, 2018 to 2030 (USD Million) Chapter 5. Epilepsy Drugs Market: Regional Estimates & Trend Analysis, by Drug 5.1. Regional Outlook 5.2. Epilepsy Drug Market by Region: Key Marketplace Takeaways 5.3. North America 5.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million) 5.3.2. U.S. 5.3.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million) 5.3.3. Canada 5.3.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million) 5.4. Europe 5.4.1. UK 5.4.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million) 5.4.2. Germany 5.4.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million) 5.4.3. France 5.4.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million) 5.4.4. Italy 5.4.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million) 5.4.5. Spain 5.4.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million) 5.4.6. Sweden 5.4.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million) 5.4.7. Norway 5.4.7.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million) 5.4.8. Denmark 5.4.8.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million) 5.5. Asia Pacific 5.5.1. Japan 5.5.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million) 5.5.2. China 5.5.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million) 5.5.3. India 5.5.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million) 5.5.4. Australia 5.5.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million) 5.5.5. Thailand 5.5.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million) 5.5.6. South Korea 5.5.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million) 5.6. Latin America 5.6.1. Brazil 5.6.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million) 5.6.2. Mexico 5.6.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million) 5.6.3. Argentina 5.6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million) 5.7. MEA 5.7.1. Saudi Arabia 5.7.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million) 5.7.2. South Africa 5.7.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million) 5.7.3. UAE 5.7.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million) 5.7.4. Kuwait 5.7.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million) Chapter 6. Competitive Landscape 6.1. Recent Developments & Impact Analysis, By Key Market Participants 6.2. Market Participant Categorization 6.2.1. UCB S.A., Belgium 6.2.1.1. Company Overview 6.2.1.2. Financial Performance 6.2.1.3. Product Benchmarking 6.2.1.4. Strategic Initiatives 6.2.2. Sanofi 6.2.2.1. Company Overview 6.2.2.2. Financial Performance 6.2.2.3. Product Benchmarking 6.2.2.4. Strategic Initiatives 6.2.3. Pfizer, Inc. 6.2.3.1. Company Overview 6.2.3.2. Financial Performance 6.2.3.3. Product Benchmarking 6.2.3.4. Strategic Initiatives 6.2.4. Otsuka America Pharmaceutical, Inc. 6.2.4.1. Company Overview 6.2.4.2. Financial Performance 6.2.4.3. Product Benchmarking 6.2.4.4. Strategic Initiatives 6.2.5. Eisai Co., Ltd. 6.2.5.1. Company Overview 6.2.5.2. Financial Performance 6.2.5.3. Product Benchmarking 6.2.5.4. Strategic Initiatives 6.2.6. Novartis AG 6.2.6.1. Company Overview 6.2.6.2. Financial Performance 6.2.6.3. Product Benchmarking 6.2.6.4. Strategic Initiatives 6.2.7. Abbott Laboratories, Inc. 6.2.7.1. Company Overview 6.2.7.2. Financial Performance 6.2.7.3. Product Benchmarking 6.2.7.4. Strategic Initiatives 6.2.8. Sanofi Aventis S.A. 6.2.8.1. Company Overview 6.2.8.2. Financial Performance 6.2.8.3. Product Benchmarking 6.2.8.4. Strategic Initiatives 6.2.9. GlaxoSmithKline plc 6.2.9.1. Company Overview 6.2.9.2. Financial Performance 6.2.9.3. Product Benchmarking 6.2.9.4. Strategic Initiatives 6.2.10. Sunovion Pharmaceuticals, Inc. 6.2.10.1. Company Overview 6.2.10.2. Financial Performance 6.2.10.3. Product Benchmarking 6.2.10.4. Strategic Initiatives 6.2.11. Jazz Pharmaceuticals plc 6.2.11.1. Company Overview 6.2.11.2. Financial Performance 6.2.11.3. Product Benchmarking 6.2.11.4. Strategic Initiatives 6.2.12. Neurelis, Inc. 6.2.12.1. Company Overview 6.2.12.2. Financial Performance 6.2.12.3. Product Benchmarking 6.2.12.4. Strategic Initiatives
ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。本レポートと同分野(医療機器)の最新刊レポート
Grand View Research社の医療機器分野での最新刊レポート
本レポートと同じKEY WORD()の最新刊レポート
よくあるご質問Grand View Research社はどのような調査会社ですか?グランドビューリサーチ(Grand View Research)は通信技術、化学品、材料、ヘルスケア、エネルギーなど広範な市場を対象にした調査報告書を出版しています。 もっと見る 調査レポートの納品までの日数はどの程度ですか?在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
注文の手続きはどのようになっていますか?1)お客様からの御問い合わせをいただきます。
お支払方法の方法はどのようになっていますか?納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
データリソース社はどのような会社ですか?当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
|